Company: ABBV
Filing Date: 2025-02-18
Form Type: 424B5
Source: 0001104659-25-014554
Chunk: 1

Company: AbbVie Inc.
Filing Date: 2025-02-18
Form: 424B5
Chunk 1
---
 discharge, defease, make a tender offer for, or otherwise repay at maturity (i) all of its 3.600% senior notes due 2025, which have a stated maturity date of May 14, 2025, in an aggregate outstanding principal amount of $3.750 billion, and/or (ii) all of its 3.800% senior notes due 2025, which have a stated maturity date of March 15, 2025, in an aggregate outstanding principal amount of $2.890 billion, and/or (iii) all of the 3.800% senior notes due 2025 of Allergan Funding SCS (formerly known as Actavis Funding SCS), which have a stated maturity date of March 15, 2025, in an aggregate principal amount of $130.225 million, and, in each case, to pay any premium and accrued and unpaid interest in respect thereof, and/or (b) for general corporate purposes. The Company may redeem some or all of each series of Notes at any time at redemption prices described in this prospectus supplement under the caption “ Description of Notes — Optional Redemption .” Investing in the Notes involves risks. Please read “Risk Factors” included or incorporated by reference herein, as described beginning on page S-5of this prospectus supplement.

| ​            | ​ | ​ | Publicoffering price(1) |   |    |   | ​ | ​ | Underwritingdiscount |   |    |   | ​ | ​ | Proceeds, beforeexpenses, to us |   |    |   | ​ |
| Per 20  Note | ​ | ​ | ​                       | ​ | %  | ​ | ​ | ​ | ​                    | ​ | %  | ​ | ​ | ​ | ​                               | ​ | %  | ​ | ​ |
| Per 20  Note | ​ | ​ | ​                       | ​ | ​% | ​ | ​ | ​ | ​                    | ​ | ​% | ​ | ​ | ​ | ​                               | ​ | ​% | ​ | ​ |
| Per 20  Note | ​ | ​ | ​                       | ​ | ​% | ​ | ​ | ​ | ​                    | ​ | ​% | ​ | ​ | ​ | ​                               | ​ | ​% | ​ | ​ |
| Per 20  Note | ​ | ​ | ​                       | ​ | ​%